date,title,source
Nov-13-18,"Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer",GlobeNewswire
Dec-03-18,What Kind Of Shareholders Own Veru Inc (NASDAQ:VERU)?,Simply Wall St.
Dec-03-18,Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil  Finasteride Tablet for Benign Prostatic Hyperplasia,GlobeNewswire
